Water soluble paclitaxel prodrugs

Patent 7384977 Issued on June 10, 2008. Estimated Expiration Date:

August 31, 2026. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Time-release chemical delivery system
Patent #: 4356166
Issued on: 10/26/1982
Inventor: Peterson , et al.

Water soluble, antineoplastic derivatives of taxol
Patent #: 4942184
Issued on: 07/17/1990
Inventor: Haugwitz, et al.

Water soluble prodrugs of camptothecin
Patent #: 4943579
Issued on: 07/24/1990
Inventor: Vishnuvajjala, et al.

Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
Patent #: 4960790
Issued on: 10/02/1990
Inventor: Stella, et al.

Water soluble derivatives of taxol
Patent #: 5059699
Issued on: 10/22/1991
Inventor: Kingston, et al.

Cytotoxic drug conjugates and their delivery to tumor cells
Patent #: 5087616
Issued on: 02/11/1992
Inventor: Myers, et al.

Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
Patent #: 5169933
Issued on: 12/08/1992
Inventor: Anderson, et al.

Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
Patent #: 5219564
Issued on: 06/15/1993
Inventor: Zalipsky, et al.

Method of treating tumors with anti-tumor effective camptothecin compounds
Patent #: 5340817
Issued on: 08/23/1994
Inventor: Wall, et al.

Polymer-bound paclitaxel derivatives
Patent #: 5362831
Issued on: 11/08/1994
Inventor: Mongelli, et al.

More ...

Inventors

Assignee

PG-TXL Company L.P.

Application

No. 11513390 filed on 08/31/2006

US Classes:

514/511, Two of the cyclos share at least three ring members (i.e., bridged)424/1.11, RADIONUCLIDE OR INTENDED RADIONUCLIDE CONTAINING; ADJUVANT OR CARRIER COMPOSITIONS; INTERMEDIATE OR PREPARATORY COMPOSITIONS424/1.65, In an organic compound424/9.1, IN VIVO DIAGNOSIS OR IN VIVO TESTING424/1.69, Attached to peptide or protein of 2+ amino acid units (e.g., dipeptide, folate, fibrinogen, transferrin, sp. enzymes); derivative thereof514/510, Polycyclo ring system514/449Oxygen containing hetero ring

Examiners

Primary: Jones, Dameron L.

Attorney, Agent or Firm

Foley & Lardner LLP

Foreign Patent References

0589281 EP 03/01/1996
0558959 EP 04/01/1997
0604910 EP 06/01/2000
64-61422 JP 03/01/1989
64-61423 JP 03/01/1989
5-000955 JP 01/01/1993
5-117385 JP 05/01/1993
5286868 JP 11/01/1993
WO 93/10121 WO 05/01/1993
WO 93-24476 WO 12/01/1993
WO 95/03036 WO 02/01/1995
WO 95-11020 WO 04/01/1995
WO 95-11924 WO 05/01/1995
WO 95/13053 WO 05/01/1995
WO 96-00080 WO 01/01/1996
WO 96/25176 WO 08/01/1996
WO 97/33552 WO 09/01/1997
WO 99/17804 WO 04/01/1999
WO 99/49901 WO 10/01/1999
WO 01/70275 WO 09/01/2001

International Classes

A01N 37/00
A61K 31/21

Abstract

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Other References

Zunino et al., “Anti-Tumor Activity of Daunorubicin Linked to Poly-L-Aspartic Acid,” Int. J. Cancer, vol. 30, 1982, pp. 465-470.
Zheng et al., “Deacetylation of Paclitaxel and Other Taxanes,” Tetrahedron Letters, vol. 36, 1995, pp. 2001-2004, © Elsevier Science Ltd.
Zhao et al., “Modified taxols. 6. preparation of water-soluble taxol phosphates,” J. Nat. Prod., vol. 54, 1991, pp. 1607-1611.
Zhang et al., “An investigation of the antitumor activity and biodistribution of polymeric micellar paciltaxel,” Cancer Chemother. Pharmacol, vol. 40, 1997, pp. 80-86 © Springer-Verlag.
Yu, “Effect of polymer structure on antitumor activity of polyaminio acid-paclitaxel conjugates,” Proc. Amer. Assoc. Cancer Research, vol. 39, 1998, p. 167, Abstract No. 1144.
Yang et al., “Diagnostic and therapeutic potential of poly(benzyl L-glutamate),” J. Pharm. Sci, vol. 83, 1994, pp. 328-331 © American Chemical Society and American Pharmaceutical Association.
Yang et al., “Application of surface-modified microcapsules to target estrogen receptors,” Pharm. Res., vol. 9, 1992, p. S73, Abstract No. Biotec 2027.
Wen et al., “Potentiation of Antitumor Activity of PG-TXL with Anti-EGFR Monoclonal Antibody C225 in MDA-MB-468 Human Breast Cancer Xenograft,” Proc Am Assoc Cancer Res, vol. 41, 2000, Abstract No. 2052.
Weiss et al., “Hypersensitivity reactions from taxol,” J. Clin. Oncol., vol. 8, 1990, pp. 1263-1268 © American Society of Clinical Oncology.
Wang et al., “Recent Advances in the Discovery and Development of Topoisomerase Inhibitors as Antitumor Agents,” Medicinal Research Reviews, vol. 17, 1997, pp. 367-425, © John Wiley & Sons, Inc.
Wall et al., “Plant Antitumor Agents. 30. ^TR.DSynthesis and Structure Activity of Novel Camptothecin Analogs,” Journal of Medicinal Chemistry, vol. 36, 1993, pp. 2689-2700, © American Chemical Society.
Wadkins et al., “Water Soluble 20(S)-Glycinate Esters of 10,11-Methylenedioxycamptothecins Are Highly Active Against Human Breast Cancer Xenografts” Cancer Research, vol. 59, 1999, pp. 3424-3428.
Vyas et al., “Phosphate-activated prodrugs of paclitaxel,” Taxene Anticancer Agents, Chapter 9, 1995, pp. 124-137 © American Chemical Society.
Van Heeswijk et al., The Synthesis and Characterization of Polypeptide-Adriamycin Conjugates and its Complexes with Adriamycin. Part 1, Journal of Controlled Release, vol. 1, 1985, pp. 301-315 © Elsevier Science Publishers B.V.
Todd et al., “Phase I and pharmacological Study of CT-2103, a poly (L-glutamic Acid)-paclitaxel conjugate,” Journal of Clinical Oncology, vol. 439, 2001.
Singer et al., “Conjugation of Camptothecins to Poly-(L-Glutamic Acid),” Annals of the New York Academy of Sciences, vol. 922, 2000, pp. 135-150, © The New York Academy of Sciences.
Singer et al., “Poly-L-Glutamic Acid Paclitaxel Conjugate (PG-TXL): A water-soluble biodegradable conjugate with decreased toxicity and enhanced efficacy,” 4th International Symposium on Polymer Therapeutics, 2000.
Shi, “Poly (L-glutamic acid)-paclitaxel and paclitaxel have different pharmacological properties,” Proc. Amer. Assoc. for Cancer Research, vol. 39, 1998, p. 189, Abstract No. 1294.
Sharma et al., “Noveltaxol formulations: preparation and characterization of taxol-containing liposomes,” Pharm. Res., vol. 11, 1994, pp. 889-896 © Plenum Publishing Corp.
Shaffer et al., “In vivo identification of monoglutamyl paclitaxel metabolite from poly-L-glutamic acid-paclitaxel (CT-2103) in tumor bearing mice,” Proceedings of the 49^thASMA Conference on Mass Spectrometry and Allied Topics, A010970, 2001.
Serruys et al., “A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease,” N. Engl. J. Med., vol. 331, 1994, pp. 489-495 © The Massachusetts Medical Society.
Scudiero et al., “Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines,” Cancer Research, vol. 48, 1988, pp. 4827-4833.
Rose et al., “Preclinical antitumor activity of water-soluble paclitaxel derivatives,” Cancer Chemother. Pharmacol., vol. 39, 1997, pp. 486-492 © Springer Verlag.
Reynolds et al., “Polymers help guide cancer drugs to tumor targets- and keep them there,” J. Natl. Cancer Institute, vol. 87, 1995, pp. 1582-1584.
Pratesi et al., “Poly-L-Aspartic Acid as a Carrier for Doxorubicin: A Comparative in vivo Study of Free and Polymer-Bound Drug,” Br. J. Cancer, vol. 52, 1985, pp. 841-848 © The Macmillan Press Ltd.
Phillips-Hughes et al., “Restenosis: pathophysiology and preventive strategies,” JVIR, vol. 7, 1996, pp. 321-333 © SCVIR.
Pesenti et al., “Synthesis and biological activity of water soluble polymer-bound taxol derivatives,” Proc. Amer. Assoc. Cancer Res., vol. 36, 1995, p. 307, Abstract No. 1824.
Oliver et al., “Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, Taxol,” Cellular Immunology, vol. 157, 1994, pp. 291-299 © Academic Press, Inc.
Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assay,” J. Immunol. Methods, vol. 65, 1983, pp. 55-63 © Elsevier Science Publishers B.V.
Morimoto et al., “Antitumor agent poly (amino acid) conjugates as a drug carrier in cancer chemotherapy,” J. Pharm. Dyn., vol. 7, 1984, pp. 688-698.
Multani et al., “Paclitaxel and water-soluble poly (L-gluatmic acid)-paclitaxel, induce direct chromosomal Abnormalities and cell death in a murine metastatic melanoma cell line,” Anticancer Res, vol. 17, 1997, pp. 4269-4274.
Mason et al., “Poly (L-glutamic Acid)-paclitaxel dramatically enhances the anti-tumor efficacy of radiotherapy,” AACR—NCI—EORTC, vol. 397, 2001, Miami Beach, Florida.
Mathew et al., “Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity,” J. Med. Chem., vol. 35, 1992, pp. 145-151 © American Chemical Society.
Magri et al., “Modified Taxols. 2. Oxidation Products of Taxol,” J. Org. Chem., vol. 51, 1986, pp. 797-802 © American Chemical Society.
Maeda et al., “Tumoritropic and lymphotropic principles of macromolecular drugs,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 6, 1989, pp. 193-210 © CRC Press.
Li et al., “Potentiation of ovarian OCa-1 tumor radioresponse by poly (L-glutamic acid)-paclitaxel conjugate,” Int.J Radiat. Oncol. Biol. Phys., vol. 48, 2000, pp. 1119-1126 © Elsevier Science Inc.
Li et al., “Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor,” Cancer Chemother Pharmacol, vol. 46, 2000, pp. 416-422 © Springer-Verlag.
Li et al., “Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy,” Clin Cancer Res, vol. 6, 2000, pp. 2829-2834.
Li et al., “Antitumor activity of Poly(L-glutamic acid)-Paclitaxel on syngeneic and xenografted tumors,” Clin Cancer Res, vol. 5, 1999, pp. 891-897.
Li et al., “Enhancement of tumor radioresponse of a murine ovarian carcinoma by poly(L-glutamic acid)-paclitaxel conjugate,” Ninth International Symposium on Recent Advances in Drug Delivery Systems, 1999, Salt Lake City, UT.
Li et al., “Antitumor activity of Poly(L-glutamic acid)-Paclitaxel on syngeneic and xenografted tumors,” Proc Am Assoc Cancer Res, vol. 40, 1999, Abstract No. 1909.
Li et al., “Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paciitaxei prodrug,” Anticancer Drugs, vol. 7, 1996, pp. 642-618.
Li et al., “Water-soluble polyglutamic acid paclitaxel conjugate (PGA-paclitaxel): antitumor regression in rats braeing 13762 mammary carcinoma,” American Association Pharmaceutical Scientists Meeting, vol. 13, 1996, p. S368.
Li et al., “Synthesis, biodistribution and imaging properties of indium-111-DTPA-paclitaxel in mice bearing mammary tumors,” J. Nucl. Med., vol. 38, 1997, pp. 1042-1047.
Li et al., “Formation and characterization of CDDP loaded poly(benzyl L-glutamate) and poly (di-tactic acid) microcarpsules for chemoembolzation,” Proc. Amer. Assoc. Cancer Res., vol. 35, 1994, p. 336, Abstract No. 2003.
Li et al., “Cytotoxic and antitumor activity of water-soluble paclitaxel prodrug,” Proc. Amer. Assoc. Cancer Res, vol. 37, 1996, pp. 376-377, Abstract No. 2570.
Li et al., “Synthesis and evaluation of PEG-paclitaxel conjugate as a water-soluble paclitaxel prodrug,” Proc. Amer. Assoc. Cancer Res, vol. 37, 1996, p. 376, Abstract No. 2569.
Li et al., “Complete Regression of Well-Established Tumors Using a Novel Water-Soluble Poly-(L-Glutamic Acid)-Paclitaxel Conjugate,” Cancer Research, vol. 58, 1998, pp. 2404-2409.
Kuang et al., “Poly(benzyl-l-glutamate) microcapsules: Their diagnostic and therapeutic potential,” Pharm. Res., vol. 10, 1993, p. S-191, Abstract PDD 7066 © Plenum Press.
Kouskoff et al., “Organ-specific disease provoked by systemic autoimmunity,” Cell, vol. 87, 1996, pp. 811-822 © Cell Press.
Kopecek, “The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery,” J. Controlled Release, vol. 11, 1990, pp. 279-290 © Elsevier Science Publishers B.V.
Ke et al., “Potentiation of radioresponse by polymer-drug conjugates,” J. Control Release, vol. 74, 2001, pp. 237-242 © Elsevier Science B.V.
Ke et al., “Schedule-independent radiosensitization of a murine ovarian OCa-1 tumor by PG-TXL,” Proc Am Assoc Cancer Res, vol. 40, 1999, Abstract No. 4223.
Ke et al., “Elevated serum VEGF as a prognosis marker in combined radiation and PG-TXL (CT-2103) therapy in mice with murine ovarian OCa-1 tumor,” Proc Amer Assoc Cancer Res, vol. 42, 2001, Abstract No. 3873.
Kato et al., “Antitumor activity of 1-β_D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative,” Cancer Res., vol. 44, 1984, pp. 25-30
Horwitz et al., “Taxol, mechanisms of action and resistance,” J. Natl. Cancer Inst. Monographs, vol. 15, 1993, pp. 15-61.
Höfle et al., “Epothilone A and B—novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution,” Angew. Chem. Int. Ed. Engl., vol. 35, 1996, pp. 1567-1569 © VCH Verlagsgesellschaft mbH.
Hoes et al., “Optimization of macromolecular prodrugs of the antitumor antibiotic adriamycin,” J. Controlled Release, vol. 2, 1985, pp. 205-213 © Elsevier Science Publishers B.V.
Hirano et al., “Polymeric derivatives of activated cyclophosphamide as drug delivery systems in antitumor therapy pharmacologically active polymers, 20,” Makromol. Chem., vol. 180, 1979, pp. 1125-1130 © Hüthig & Wepf Verlag, Basel, Heidelberg.
Greenwald, “Camptothecin-20-PEG Ester Transport Forms: the Effect of Spacer Groups on Antitumor Activity”, Bioorganic & Medicinal Chemistry, vol. 6, 1998, pp. 551-562 © Elsevier Science Ltd.
Greenwald et al., “Stereoselective acylation of 20-(S)-camptothecin with amino acid derivatives using scandium triflate/DMAP,” Tetrahedron: Asymmetry, vol. 9, 1998, pp. 915-918, © Elsevier Science Ltd.
Greenwald et al., “Highly Water Soluble Taxol Derivatives: 2′-polyethyleneglycol esters as potential prodrugs,” Bioorganic & Medicinal Chemistry Letters, vol. 4, 1994, pp. 2465-2470 © Elsevier Science Ltd.
Greenwald et al., “Highly Water Soluble Taxol Derivatives: 2′-Polyethylene Glycol Esters as Potential Products,” J. Org. Chem., vol. 60, 1995, pp. 331-336 © American Chemical Society.
Greenwald et al., “Drug Delivery Systems: Water Soluble Taxol 2′-Poly(Ethylene Glycol) Ester Prodrugs-Design and in Vivo Effectiveness,” J. Med Chem., vol. 39, 1996, pp. 424.431 © American Chemical Society.
Greenwald et al., “Drug Delivery Systems. 2. Camptothecin 20-0-Poly(ethylene glycol) Ester Transport Forms,” J. Med. Chem., vol. 39, 1996, pp. 1938-1940, © American Chemical Society.
Greenwald et al., “Camptothecin-20-PEG Ester Transport Forms: the Effect of Spacer Groups on Antitumor Activity,” Bioorganic & Medicinal Chemistry, vol. 6, 1998, pp. 551-562, © Elsevier Science Ltd.
Goldspiel, “Pharmaceutical Issues: Preparation, Administration, Stability, and Compatibility with Other Medications,” Ann. Pharmacotherapy, vol. 28, 1994, pp. S23-26, © Harvey Whitney Books Company.
Gilbert et al., “Novel water soluble paclitaxel derivatives: Evaluation of PEG-paclitaxel's in vitro and in vivo effects,” Proc. Amer. Assoc. Cancer Res., vol. 38, 1997, p. 225, Abstract #1512.
Fidler et al., “The Biology of Cancewr Invasion and Metastasis,” Adv. Cancer Res., vol. 28, 1978, pp. 149-250 © Academic Press, Inc.
Eiseman et al., “Plasma pharmcokinetics and tissue distribution of paclitaxel in CD2F1 mice,” Cancer Chemother. Pharmacol., vol. 34, 1994, pp. 465-471 © Springer-Verlag.
Duncan et al., “Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the Laboratory to Clinic,” Journal of Controlled Release, vol. 74, 2001, pp. 135-146, © Elsevier Science B.V.
Deutsch et al., “Synthesis of Congeners of Prodrugs. 3. Water-Soluble Prodrugs of Taxol with Potent Antitumor Activity,” J. Med. Chem., vol. 32, 1989, pp. 788-792 © American Chemical Society.
De Vries et al., “Pharmacokinetcis (PK) and biodistribution of poly-(L)-glutamic acid (PG) paclitaxesl (TXL) (CT-2103) in mice with subcutaneous B-16 melanomas,” Proceedings of the 11^thAACR-NCI-EORTC Symposium, 2000 Amsterdam, Netherlands.
De Vries et al., “Optimization of the anti-tumor activity of water-soluble poly L-glutamic acid (PG)- paclitaxel (TXL) conjugates,” AACR-NCI-EORTC 92, 1999, pp. 22, Abstract No. 451, Washington, DC.
De Vries et al., “CT-2103: A water soluble poly-L-glutamic acid (PG)-Paclitaxesl (TXL) conjugate has enhanced efficacy on MDR-1+human colon carcinoma cell line xenografts compared to free TXL,” AACR, 2001, Abstract No. 462.
De Vries et al., “Conjugation of Docetaxel (DTXL) to Poly L-Glutamic Acid (PG) Increases Anti-Tumor Efficacy,” Proceedings of the American Association for Cancer Research, vol. 41, 2000, p. 323, Abstract No. 2051.
De Bono et al., “Phase I Pharmacokinetic (PK) Study of Mag-CPT-(PNO 166148) A Polymer Derivative of Camptothecin (CPT),” Pharmicia, date not available.
Cortes et al., “Docetaxal,” J. of Clinical Oncology, vol. 13, 1995, pp. 2643-2655 © American Society of Clinical Oncology.
Conover et al., “Camptothecin Delivery Systems: The Antitumor Activity of a Camptothecin-20-0-Polyethylene Glycol Ester Transport Form,” Anticancer Research, vol. 17, 1997, pp. 3361-3368.
Conover et al., “Camptothecin Delivery Systems: The Utility of Amino Acid Spacers for the Conjugation of Camptothecin with Polyethylene Glycol to Create Prodrugs,” Anti-Cancer Drug Design, vol. 14, 1999, pp. 499-506, ® Oxford University Press.
Conover et al., “Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker,” Cancer Chemother Pharmacol, vol. 42, 1998, pp. 407-414, © Springer-Verlag.
Caiolfa et al., “Polymer-bound camptothecin: Initial biodistribution and antitumor activity studies,” Journal of Controlled Release, vol. 65, 2000, pp. 105-119, © Elsevier Science B.V.
Bom et al., “The Novel Silatecan 7-tert-Butyldimethylsilyl-10-hydroxycamptothecin Displays High Lipophilicity, Improved Human Blood Stability, and Potent Anticancer Activity,” Journal of Medicinal Chemistry, vol. 43, No. 21, 2000, pp. 3970-3980, © American Chemical Society.
Bartoli et al., “In Vitro and In Vivo Antitumoral Activity of Free, and Encapsulated Taxol,” J. Microencapsulation, vol. 7, 1990, pp. 191-197 © Taylor & Francis Ltd.
Balog et al., “Total Synthesis of (-) Epothilone A,” Angew. Chem. Int. Ed. Engl., vol. 35, 1996, pp. 2801-2803 © VCH Verlagsgesellschaft mbH, Weinheim.